Synonyms: BHV-4157 | BHV-4157a | BHV4157 | BHV4157a | FC-4157 | trigriluzole
Compound class:
Synthetic organic
Comment: Troriluzole (BHV-4157) is a prodrug of the voltage-dependent calcium channel blocker riluzole. Chemically it is riluzole conjugated to a tripeptide carrier (IUPAC sequence H-Gly-Gly-Sar-Unk, where Unk = the riluzole component), and the active moiety is released by peptidases in vivo. The prodrug is more stable than riluzole and is suitable for once-daily dosing.
|
|
No information available. |
Summary of Clinical Use |
Troriluzole has progressed to clinical evaluation- max Phase 3 as of January 2021. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04708834 | Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder | Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
NCT03829241 | Randomized Trial of Adult Subjects With Generalized Anxiety Disorder | Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
NCT03299166 | BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder | Phase 2/Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. | ||
NCT03605667 | Study of BHV-4157 in Alzheimer's Disease | Phase 2/Phase 3 Interventional | Biohaven Pharmaceuticals, Inc. |